Clinical trials: Overload
Chronic Heart Failure, Fluid Overload
Naturally Controlled Decongestion Using Renal Independent System in ADHF Patients, a European Registry
The AquaPass is a non-invasive, renal-intended system designed to enhance fluid transfer through the skin, by increasing sweat rate, to treat fluid overload in heart failure patients.
- Conditions
- Chronic Heart Failure, Fluid Overload, Acute Decompensated Heart Failure, Edema
- Trial name
- REFORM-HF II (NCT06401109)
- Testing
- AquaPass
- Volunteers
- 30 people
- Sponsor
- AquaPass Medical Ltd.
Cardiac Iron Overload
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
This study will evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed be deferasirox monotherapy in patients with severe iron overload due to chronic blood transfusions.
- Trial name
- HYPERION (NCT01254227)
- Testing
- Deferasirox and Deferoxamine
- Where
- 15 sites in Canada, Egypt and 6 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Non-transfusion Dependent Thalassemia
Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
CICL670A2209: This study will evaluate the safety and efficacy of deferasirox in non-transfusion dependent thalassemia patients with iron overload.
- Trial name
- THALASSA (NCT00873041)
- Testing
- deferasirox
- Where
- 21 sites in United States, Greece and 7 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Transfusional Iron Overload
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
A 1-year randomized Phase IIa core trial followed by a prolongation of 5 to 9 months was conducted to investigate the efficacy and safety of deferasirox in patients aged ≥ 18 years with transfusion-dependent iron overload.
- Trial name
- NCT00379483
- Testing
- Deferasirox
- Where
- 4 sites in Italy
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure (for Example, Fluid Overload), Heart Failure
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF)…
- Conditions
- Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload
- Trial name
- REVERSE-HF (NCT05318105)
- Testing
- Aquadex Smartflow® System, IV Loop Diuretics
- Where
- 15 sites in United States
- Volunteers
- 167 people
- Sponsor
- Nuwellis, Inc.
Iron Overload, Hemoglobinopathies
Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group
A prospective, observational, comparative study with no intervention.The objective of the study to compare the efficiency of detecting glycemic abnormalities using Continuous Glucose Monitoring (CGMs) versus Oral Glucose…
- Conditions
- Iron Overload, Hemoglobinopathies, Lymphoma, Acute Lymphoblastic Leukemia
- Trial name
- CGMs (NCT03141398)
- Testing
- Continuous Glucose Monitoring (CGM), Oral Glucose Tolerance Test (OGTT), T2* MRI of the Pancreas
- Sponsor
- Hamad Medical Corporation
Heart Failure, Volume Overload
Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion
Feasibility and safety study of the alfapump DSR system in the treatment of volume overloaded heart failure subjects receiving high doses of loop diuretics.
- Trial name
- SAHARA (NCT04882358)
- Testing
- ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM, SGLT2 inhibitor
- Where
- 2 sites in Georgia
- Volunteers
- 24 people
- Sponsor
- Sequana Medical N.V.
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
This study is researching an experimental drug called REGN7999 (called "study drug"). The study is focused on patients with non-transfusion dependent beta-thalassemia.
- Trial name
- FERVENT-1 (NCT06421636)
- Testing
- REGN7999
- Where
- 26 sites in United States, Georgia and 7 more
- Volunteers
- 19 people
- Sponsor
- Regeneron Pharmaceuticals
Hemochromatosis
Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
Comparison of efficacy and toxicity of the combination treatment of deferiprone and desferrioxamine with the single agent treatment of either drug
- Trial name
- NCT00350662
- Testing
- Deferiprone (L1), Desferrioxamine
- Where
- 2 sites in Egypt, Turkey (Türkiye)
- Volunteers
- 95 people
- Sponsor
- Lipomed
Beta-Thalassemia
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
This study is a Phase 2 multicenter, randomized, open-label, parallel-group study. The primary objective of the study is to evaluate the effect of LJPC-401 (synthetic human hepcidin) on iron levels in patients with…
- Trial name
- NCT03381833
- Testing
- LJPC-401
- Where
- 22 sites in United States, Australia and 6 more
- Volunteers
- 84 people
- Sponsor
- La Jolla Pharmaceutical Company
Chronic Iron Overload
Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation
Extend evaluation of deferasirox film-coated tablet (FCT) formulation
- Trial name
- NCT02720536
- Testing
- Deferasirox
- Where
- 14 sites in Austria, Greece and 1 more
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Transfusional Iron Overload, Beta-thalassemia
Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
The purpose of this research study is to evaluate the safety of two doses of FBS0701, a new oral iron chelator, and its effectiveness in clearing iron from the liver.
- Trial name
- NCT01186419
- Testing
- SPD602 (FBS0701, SSP-004184)
- Where
- 9 sites in United States, Italy and 3 more
- Volunteers
- 51 people
- Sponsor
- Shire
Heart Failure
Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure.
To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.
- Trial name
- NCT05712746
- Testing
- Samtasu for I.V. infusion
- Where
- Japan
- Volunteers
- 1,600 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Chronic Iron Overload
Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials
The objective of this survey is to assess the knowledge of HCPs in relation to the recommended posology and biological monitoring for Exjade, based on the current locally valid Exjade educational materials (including the…
- Trial name
- NCT06215287
- Testing
- Physician survey
- Where
- Switzerland
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
Hereditary Hemochromatosis
A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis
This study will be conducted in two parts run in parallel. Part 1 of the study (Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose) will enroll healthy volunteers in 3 sequential dose escalating…
- Trial name
- NCT07371793
- Testing
- BBI-001
- Where
- Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bond Biosciences
Hypertension, Pulmonary, Right Ventricular Overload
The Prevalence of Pulmonary Hypertension in Patients With COVID-19.
The virus infection Covid-19 fills our hospitals and intensive care departments in a very unique way and there is a lack of essential insight into the pathophysiology of the disease.
- Conditions
- Hypertension, Pulmonary, Right Ventricular Overload, COVID
- Trial name
- NCT04459364
- Where
- Sweden
- Volunteers
- 67 people
- Sponsor
- Attgeno AB
Myelodysplastic Syndrome, Transfusional Iron Overload
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
The objective of the study is to evaluate and compare the frequency and severity of GI adverse events in different dose administration regimens.
- Trial name
- MACS1574 (NCT01326845)
- Testing
- Deferasirox
- Where
- 10 sites in France, Italy and 2 more
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Congestive Heart Failure
Reprieve ADHF EFS IDE
This is a prospective, single arm, early feasibility study (EFS) designed to evaluate the safety and device performance of The RenalGuard System in the management of patients admitted with signs and symptoms of congestive heart…
- Trial name
- NCT03866551
- Testing
- Reprieve Cardiovascular System
- Volunteers
- 40 people
- Sponsor
- CardioRenal Systems, Inc.
Myelodysplastic Syndrome, Thalassemia
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
This study will evaluate the efficacy and safety of deferasirox in patients with MDS, thalassemia and rare anemia patients with transfusion iron overload.
- Trial name
- NCT01250951
- Testing
- Deferasirox
- Where
- 2 sites in Russia
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Fluid Overload
Ultrafiltration Therapy Registry Using Aquadex (ULTRA-Peds)
The ULTRA-Peds registry will employ a multi-center, single-arm, open-label, observational design to capture baseline, procedural and follow-up data on pediatric patients that have been treated (i.e., retrospective data from…
- Trial name
- ULTRA-Peds (NCT04644731)
- Testing
- Aquadex™ System
- Where
- 7 sites in United States
- Volunteers
- 97 people
- Sponsor
- Nuwellis, Inc.